Leerink Partnrs Downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks.com reports.

Several other research firms have also recently weighed in on REGN. JPMorgan Chase & Co. raised their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Morgan Stanley decreased their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Barclays raised their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Leerink Partners reissued a “market perform” rating and set a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday. Finally, Truist Financial reissued a “buy” rating and set a $1,200.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,118.62.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $1,045.98 on Tuesday. The business’s 50-day moving average price is $1,130.96 and its two-hundred day moving average price is $1,034.01. Regeneron Pharmaceuticals has a twelve month low of $769.19 and a twelve month high of $1,211.20. The stock has a market cap of $115.31 billion, a P/E ratio of 30.90, a PEG ratio of 3.72 and a beta of 0.12. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter last year, the firm posted $8.79 EPS. The company’s revenue was up 12.3% compared to the same quarter last year. As a group, equities analysts predict that Regeneron Pharmaceuticals will post 37.8 EPS for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the transaction, the director now owns 17,882 shares in the company, valued at approximately $18,941,329.68. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the transaction, the director now owns 17,882 shares in the company, valued at approximately $18,941,329.68. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,270 shares of company stock worth $10,695,833. 7.48% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in REGN. Global Assets Advisory LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at $339,594,000. Capital International Investors raised its stake in Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after buying an additional 213,038 shares during the last quarter. First Trust Advisors LP raised its stake in Regeneron Pharmaceuticals by 115.2% during the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after buying an additional 195,902 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after buying an additional 184,561 shares during the last quarter. Finally, TD Asset Management Inc raised its stake in Regeneron Pharmaceuticals by 162.9% during the first quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock valued at $259,402,000 after buying an additional 166,998 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.